ELDN RSI Chart
Last 7 days
31.6%
Last 30 days
93.6%
Last 90 days
66.1%
Trailing 12 Months
35.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2017 | 136.0K | 0 | 0 | 0 |
2016 | 188.0K | 212.0K | 196.0K | 164.0K |
2015 | 168.0K | 170.0K | 172.0K | 174.0K |
2014 | 0 | 0 | 0 | 166.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 05, 2023 | bvf partners l p/il | bought | - | - | 1,978,930 | - |
Nov 23, 2022 | perrin steven | bought | 2,596 | 2.5969 | 1,000 | president |
Dec 20, 2021 | gros david-alexandre c | bought | 8,960 | 4.48 | 2,000 | chief executive officer |
Aug 17, 2021 | gros david-alexandre c | bought | 24,840 | 6.21 | 4,000 | chief executive officer |
Jun 11, 2021 | little paul sean | bought | 88,700 | 8.87 | 10,000 | chief financial officer |
Jun 09, 2021 | gros david-alexandre c | bought | 24,030 | 8.01 | 3,000 | chief executive officer |
Which funds bought or sold ELDN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | unchanged | - | 11,620 | 92,066 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -31.14 | -8,851 | 32,923 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -62.96 | - | - | -% |
May 15, 2024 | BVF INC/IL | unchanged | - | 1,124,940 | 8,913,020 | 0.24% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -39.32 | -12,579 | 28,582 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -21,204 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 0.67 | 1,543 | 11,688 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | added | 4.93 | 791,620 | 4,731,820 | 0.06% |
May 15, 2024 | Schonfeld Strategic Advisors LLC | new | - | 104,648 | 104,648 | -% |
May 15, 2024 | Woodline Partners LP | reduced | -5.43 | 102,182 | 1,342,990 | 0.01% |
Unveiling Eledon Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Eledon Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Eledon Pharmaceuticals, Inc. News
Income Statement (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2017Q1 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q2 | 2014Q1 |
Revenue | 13.0% | 26,000 | 23,000 | 38,000 | 49,000 | 54,000 | 55,000 | 54,000 | 25,000 | 40,000 | 37,000 | 34,000 | 45,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -9.3% | 81.00 | 89.00 | 96.00 | 107 | 82.00 | 93.00 | 150 | 155 | 161 | 171 | 177 | 184 | 192 | 197 | 193 | 11.00 | 14.00 | 11.00 | 15.00 | 18.00 | 13.00 |
Current Assets | -14.5% | 48.00 | 56.00 | 63.00 | 74.00 | 49.00 | 60.00 | 68.00 | 73.00 | 79.00 | 88.00 | 96.00 | 103 | 110 | 116 | 115 | 10.00 | 13.00 | 10.00 | 12.00 | 15.00 | 10.00 |
Cash Equivalents | 22.6% | 6.00 | 5.00 | 4.00 | 41.00 | 47.00 | 56.00 | 66.00 | 70.00 | 77.00 | 85.00 | 94.00 | 101 | 109 | 114 | 114 | 9.00 | 12.00 | 9.00 | 11.00 | 14.00 | 14.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | - | - | - | - | - | - | - | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 44.00 | - | - | - | 2.00 | 2.00 | 2.00 |
Liabilities | 6.2% | 6.00 | 6.00 | 5.00 | 7.00 | 8.00 | 9.00 | 8.00 | 5.00 | 5.00 | 7.00 | 6.00 | 6.00 | 8.00 | 7.00 | 6.00 | 1.00 | 2.00 | 1.00 | 2.00 | 2.00 | 4.00 |
Current Liabilities | 9.0% | 4.00 | 4.00 | 3.00 | 5.00 | 5.00 | 6.00 | 6.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 2.00 | 6.00 | 1.00 | 2.00 | 1.00 | 2.00 | 2.00 | 3.00 |
Shareholder's Equity | -10.3% | 75.00 | 83.00 | 91.00 | 100 | 75.00 | 84.00 | 141 | 149 | 156 | 164 | 171 | 179 | 184 | 191 | 22.00 | 9.00 | 12.00 | 9.00 | 13.00 | 16.00 | 10.00 |
Retained Earnings | -4.2% | -253 | -243 | -233 | -223 | -213 | -202 | -144 | -134 | -124 | -114 | -106 | -96.30 | -88.89 | -80.39 | -74.49 | -68.34 | -65.76 | -57.58 | -53.44 | -50.54 | -46.45 |
Additional Paid-In Capital | 0.5% | 328 | 327 | 325 | 323 | 288 | 287 | 286 | 283 | 281 | 279 | 277 | 275 | 273 | 271 | 96.00 | 78.00 | 77.00 | 67.00 | 67.00 | 67.00 | 56.00 |
Shares Outstanding | 2.5% | 25.00 | 24.00 | 24.00 | 23.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 15.00 | 15.00 | 15.00 | 15.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 26.00 | - | - | - | 34.00 | - | - | - | 113 | - | - | - | 7.00 | - | - | - | 10.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 4.3% | -8,741 | -9,131 | -12,251 | -8,221 | -9,924 | -9,480 | -4,571 | -6,217 | -8,156 | -9,208 | -7,093 | -7,446 | -5,166 | -9,433 | -561 | -3,021 | -2,197 | -2,023 | -2,889 | -4,922 | -4,023 |
Share Based Compensation | -100.0% | - | 1,710 | 1,734 | 1,720 | 1,381 | 1,474 | 2,185 | 2,308 | 2,186 | 2,053 | 2,043 | 2,034 | 1,774 | 1,659 | 878 | 197 | 437 | 243 | 227 | 627 | 211 |
Cashflow From Investing | -2.9% | 9,783 | 10,076 | -25,029 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | - | 1.00 | - | - | - | - | - | - | - | - | - | 1.00 | - | -450 | 9,164 | 95,226 | - | 5,191 | - | - | 9,569 | 107 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
Research and development | $ 7,410 | $ 8,113 |
General and administrative | 3,459 | 2,997 |
Total operating expenses | 10,869 | 11,110 |
Loss from operations | (10,869) | (11,110) |
Other income, net | 574 | 338 |
Net loss and comprehensive loss | $ (10,295) | $ (10,772) |
Net loss per share, Basic | $ (0.34) | $ (0.75) |
Net loss per share, Diluted | $ (0.34) | $ (0.75) |
Weighted-average common shares outstanding, Basic | 29,989,400 | 14,285,905 |
Weighted Average Number of Shares Outstanding, Diluted | 29,989,400 | 14,285,905 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,655 | $ 4,612 |
Short-term investments | 37,207 | 46,490 |
Prepaid expenses and other current assets | 5,115 | 5,027 |
Total current assets | 47,977 | 56,129 |
Operating lease asset, net | 270 | 365 |
In-process research and development | 32,386 | 32,386 |
Other assets | 185 | 186 |
Total assets | 80,818 | 89,066 |
Current liabilities: | ||
Accounts payable | 1,864 | 967 |
Current operating lease liabilities | 284 | 383 |
Accrued expenses and other liabilities | 2,099 | 2,545 |
Total current liabilities | 4,247 | 3,895 |
Deferred tax liabilities | 1,752 | 1,752 |
Total liabilities | 5,999 | 5,647 |
Commitments and contingencies (Note 8) | ||
Stockholders’ equity: | ||
Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 24,813,130 and 24,213,130 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 25 | 24 |
Additional paid-in capital | 328,280 | 326,586 |
Accumulated deficit | (253,486) | (243,191) |
Total stockholders’ equity | 74,819 | 83,419 |
Total liabilities and stockholders’ equity | 80,818 | 89,066 |
Series X1 Non-voting Convertible Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred stock, value | ||
Series X Non-voting Convertible Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred stock, value |